Innovative biomedical scientist specializing in CRISPR/Cas based genetic engineering with a focus on single nucleotide precision variant detection. Pioneered the development of the FnCas9 Editor Linked Uniform Detection Assay (FELUDA), a groundbreaking low-cost SARS-CoV-2 detection test, and the Rapid Variant Assay (RAY) for robust diagnosis of monogenic and infectious disorders. Currently exploring novel applications of CRISPR/Cas9 technology, including the concept of the CRISPR/Cas9 Utilizing Human Body Sticker (CRISticker) for visually identifying pathogenic variants in a sequencing-free manner. Excited about leveraging multiplexable assays to advance clinical research, disease genotyping, microbial infection surveillance, food safety, and industrial biotechnology.
A stream of the startup world with founder voices, stories, news, and raw insights.
eChai Ventures partners with select brands as their growth partner - working together to explore new ideas, open doors, and build momentum across the startup ecosystem.